Findings

What do systematic reviews say?

240 questions · 247 findings · 23 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 35 · 14.2%GRADE not reported 13 · 5.3%Very low 50 · 20.2%Low 71 · 28.7%Moderate 65 · 26.3%High 13 · 5.3%

Intervention not reported

Placebo · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

End‐of‐treatment response · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Treatment discontinuation · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Serious adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation

Annualized joint Bleeding Rate (AjBR) · children or adults with hemophilia A

Prophylaxis with standard therapeutic factor concentrate showed no clear difference in AJBR compared with pegylated liposome FVIII formulation (low certainty).

1 finding from 1 review

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 143 participants
Low

Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation

ABR · children or adults with hemophilia A

Prophylaxis with standard therapeutic factor concentrate showed no clear difference in ABR compared with pegylated liposome FVIII formulation (low certainty).

1 finding from 1 review

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 143 participants
Low

Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation

Any reported adverse effects · children or adults with hemophilia A

1 finding from 1 review

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 143 participants
Low

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in progression of Kaposi's sarcoma compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.07, 15.73]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ complete response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 2.08 [0.2, 21.5]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ partial response compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.04 [0.5, 2.17]
1 study · 49 participants
Moderate

HAART + paclitaxel vs HAART + pegylated liposomal doxorubicin

Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + paclitaxel showed no clear difference in clinical response ‐ stable disease compared with HAART + pegylated liposomal doxorubicin (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.63 [0.27, 1.45]
1 study · 49 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.93 [0.83, 1.04]
5 studies · 2006 participants
Moderate

Summary of findings 2: PLD alone vs other conventional chemotherapy

Quality of life · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 2: PLD alone vs other conventional chemotherapy

Overall severe adverse events (grade > 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes overall severe adverse events (grade > 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 964 participants
Very low

Summary of findings 2: PLD alone vs other conventional chemotherapy

Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes anaemia (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1968 participants
Very low

Summary of findings 2: PLD alone vs other conventional chemotherapy

Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2184 participants
Very low

Summary of findings 2: PLD alone vs other conventional chemotherapy

Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1222 participants
Very low

Summary of findings 1: PLD with chemotherapy vs PLD alone

Overall survival (OS) · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.92 [0.7, 1.21]
1 study · 242 participants
Moderate